Navigation Links
Bristol-Myers Squibb to Announce Results for the First Quarter of 2008 on April 24
Date:4/17/2008

NEW YORK, April 17 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the first quarter of 2008 on Thursday, April 24. During a 10:30 a.m. (ET) conference call on April 24, company executives will review financial information and will address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at http://www.bms.com/ir or by dialing 913-312-0861, confirmation code: 4556649. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 2 p.m. (ET) on April 24 through midnight (ET) on May 8. The replay will be available through http://www.bms.com/ir or by dialing 402-280-9013, confirmation code: 4556649.

Bristol-Myers Squibb is a global biopharmaceutical and related health care products company whose mission is to extend and enhance human life.


'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Bristol-Myers Squibb to Present at Healthcare Conferences
2. Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
3. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
4. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
5. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
6. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
7. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
8. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
9. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
10. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
11. Bristol-Myers Squibb Announces Dividend

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...., Dec. 1 OrbusNeich today announc...domized clinical trial of the Combo Bio-engineered...ospective, randomized, multicenter study, REMEDEE ... sirolimus coat ED bio- E ngineered st E nt...ia, Australia, Europe and South America . The pri...
(Date:12/1/2009)...ness declines with age are more likely to engage i...heir misguided negative view of the aging process ... encourage them to make the most of the present in...ngs 1 by Dr. John Garry and Dr. Maria Lohan from ...published online in Springer,s Journal of Happine...
(Date:12/1/2009)...n versus cancerous lesions, researchers say , ...sed with ultrasound, elastography helps distinguis...ch reduces unnecessary biopsies, U.S. researchers ...s that are biopsied turn out to be benign, accordi... lot of room to improve specificity with ultrasoun...
(Date:12/1/2009)...easles deaths drop worldwide, but gains at risk. ... -- WHAT: Measles Initiative partners -- the Am... and Prevention, the United Nations Foundation, UN...ll announce the latest global health achievement d... 3, 2009 at 10:00 a.m. ET/16:00 CET. There will b...
(Date:12/1/2009)...KEE, Dec. 1 For most working-age A...arn an income. It is this ability to earn an inc... mortgage but also to plan and save for tomorrow,s...ding to a Northwestern Mutual survey , only 10 pe...s to protect their income by insuring it in the ev...
Breaking Medicine News(10 mins):Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:Binge drinking youths find getting old a drag 2Health News:Ultrasound With Elastography May Cut Down on Biopsies 2Health News:**MEDIA ADVISORY** Measles Initiative to Announce Major Achievement in Public Health 2Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 2Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 3
... flew in to Boston from India, on April 26, brough...ompany headquartered //in the 18th floor of the Jo... potential measles outbreak loomed before them. ... at Investors Bank & Trust, five on the same floor...
... a celebrity ship took ill after which, the ship m...cause of this sickness is thought to be Norovirus,...ed that Noroviruses render nearly 23 million Ameri...s is because they are required to report every inc...
...lion towards development of some of the province's...ed changes //. According to the incoming presi...n long-term care beds and acute care beds would he... would go towards increased funding for family doc...
...ies at London's Brunel University had designed a d...ive pills //. She says that it is an electronic de.... It also advises users what to do if they have f...of women forget to take one a month, and 10% forge...
...onal Diabetes Federation (IDF) the last 20 years h...orldwide having risen from 30 million to 230 milli...ve the most diabetes sufferers in the world. ...hat had high percentages of diabetics are predomin...
...ere are unhappy at the close tabs kept on them by ...volvement in drug peddling. "We feel insecure as.... //People have begun to generalise every single A...u University (JNU) here. "Hearing the horrib...
Other Medicine News:Health News:Global Threat of Measles Outbreak 2Health News:Diabetes On A Steady Alarming Rise From The Past 20 Years 2Health News:Crackdown on drugs makes African students insecure 2
(Date:12/1/2009)..., MORRISVILLE, N.C., Dec. 1 nCon...investigation of devices for minimally-invasive tr...initiation of a feasibility clinical trial designe...d surgical and catheter procedure, the convergent ...smal atrial fibrillation (AF). This prospective, ...
(Date:12/1/2009)..., CHICAGO, Dec. 1 At this year,...rth America (RSNA), Royal Philips Electronics ( PH...rkspace, a set of solutions that provides radiolog...mages at one workspot to help drive quality and ef...e, Philips will also highlight new capabilities fo...
(Date:12/1/2009)... , TAI,AN, China, Dec. 1 /PRNewswire-As...C Bulletin Board: CBPO) (Nasdaq: CBPO ) ("China B...asma-based biopharmaceutical companies in,China, t...val to list its,common stock on the NASDAQ Global ...es to begin trading on the NASDAQ on,Wednesday, De...
Breaking Medicine Technology:nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 2Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 2Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 4China Biologic Products Approved to List on NASDAQ 2China Biologic Products Approved to List on NASDAQ 3New Website Offers Free Tool Designed to Help Patients Speak Up 57779 1New Website Offers Free Tool Designed to Help Patients Speak Up 57779 2Experimental drug lets B cells live and lymphoma cells die 57777 1Experimental drug lets B cells live and lymphoma cells die 57777 2Experimental drug lets B cells live and lymphoma cells die 57777 3Experimental drug lets B cells live and lymphoma cells die 57777 4K State biologist to further study of cellular process that plays role in chronic disease 57773 1
...LD, IL, June 04, 2007,/PRNewswire-FirstCall/ - Car...Astellas Pharma US, Inc. ("Astellas") today,announ...clinical,study, called ACT 2. The trial evaluated ...tion of vernakalant hydrochloride,("vernakalant (i...trial fibrillation or atrial flutter between 24 ho...
...t Survival Benefit in,Liver Cancer -, CHICAGO, Jun...are Pharmaceuticals Inc. and Onyx Pharmaceuticals,...tablets significantly,extended overall survival in...primary liver cancer versus those taking placebo b...ented at the 43rd,annual meeting of the American S...
Other Medicine Technology:Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 2Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 3Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 4Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 5Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 6Nexavar Significantly Extends Overall Survival by 44% in Liver,Cancer Patients 7
Williams Micro Discectomy Instruments
... Anteater Titanium Microdiscectomy System offers s...e-aided spinal surgery. The boss anteater titanium...r of herniated intervertebral discs provides for l...a. The retractor is designed to provide low profil...
Poppen-Gelpi Laminectomy Retractor
Valin Hemilaminectomy Retractor
Medicine Products: